Edgewise Therapeutics, INC 10-K annual reports

Edgewise Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing significant progress in its muscular dystrophy and cardiac disease clinical programs, alongside increased net losses and ongoing capital requirements.

Edgewise Therapeutics' 10-K filing summarizes the company's focus on developing treatments for severe muscle diseases, highlighting clinical progress with sevasemten and EDG-7500, and detailing financial performance and future strategies.

Edgewise Therapeutics continues to advance its clinical programs for muscle diseases, reporting progress in multiple Phase 2 trials and a Phase 1 trial, while also highlighting its proprietary drug discovery platform.